US Biotech Firm To Quit London Listing After IP Deal
Biotechnology company LungLife said Tuesday that it has convened a shareholder meeting to approve plans to delist from the Alternative Investment Market of the London Stock Exchange after it reached a...To view the full article, register now.
Already a subscriber? Click here to view full article